No Data
Novi Zam: Novi Zam 2024 annual results forecast
Novi Zan 2024 annual results forecast
Nuo Wei Zhan (688105.SH): Expected loss of 12 million to 20 million yuan in 2024.
On January 16, Grid News reported that Nuo Wei Zhan (688105.SH) announced its annual performance forecast for 2024, expecting the company to achieve a net income attributable to the parent company owners of -20 million to -12 million yuan, a year-on-year reduction of losses by 71.81% to 83.09%. The net income attributable to the parent company owners after deducting non-recurring gains and losses is expected to be -85 million to -77 million yuan, a year-on-year reduction of losses by 55.90% to 60.05%. During the reporting period, the company's net income attributable to the parent company owners and the net income attributable to the parent company owners after deducting non-recurring gains and losses.
Nuo Weizan (688105.SH) has spent 0.104 billion yuan to repurchase 1.07% of its shares.
Nuo Wei Zan (688105.SH) announced that as of December 31, 2024, the company through Shanghai Securities...
Is Nanjing Vazyme Biotech (SHSE:688105) Using Debt Sensibly?
Nuo Weizan (688105.SH) plans to distribute 0.3 yuan for every 10 shares in the first three quarters, with ex-dividend and ex-rights date on December 20.
Nuoweizan (688105.SH) announced that the company plans to distribute... for every 10 shares to all Shareholders in the first three quarters of 2024.
Investors Don't See Light At End Of Nanjing Vazyme Biotech Co.,Ltd's (SHSE:688105) Tunnel And Push Stock Down 27%
